Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men

Clinical Infectious Diseases

Volumn 26, Issue 1, 1998, Pages 1-12

  Craig, William A ^a  

^a WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; CLINDAMYCIN; DALFOPRISTIN; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINUPRISTIN; TETRACYCLINE DERIVATIVE; TICARCILLIN; TOBRAMYCIN; VANCOMYCIN;

ANIMAL CELL; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; HUMAN; HUMAN CELL; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0031952586     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/516284     Document Type: Review

References (16)

1. Bundtzen RW, Gerber AU, Cohn DL, Craig WA. Postantibiotic suppression of bacterial growth. Rev Infect Dis 1981;3:28-37.
2. Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr 1986; 108:835-40.
3. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl 1991;74:63-70.
4. Ebert SC, Craig WA. Pharmacodynamic properties of antibiotics: application to drug monitoring and dosage regimen design. Infect Control Hosp Epidemiol 1990;11:319-26.
5. McDonald PJ, Craig WA, Kunin CM. Persistent effect of antibiotics on Staphylococcus aureus after exposure for limited periods of time. J infect Dis 1977;135:217-23.
6. Odenholt-Tornqvist I, Löwdin E, Cars O. Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin and amikacin. Antimicrob Agents Chemother 1992;36:1852-8.
7. McDonald PJ, Wetherall BL, Pruul H. Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes. Rev Infect Dis 1981;3:38-44.
8. Shah PM, Junghanns W, Stille W. Dosis-Wirkungs-Beziehung der Bakterizidie bei E. coli, K. pneumoniae und Staphylococcus aureus. Dtsch Med Wochenschr 1976;101:325-8.
9. Craig WA. Postantibiotic effects and the dosing of macrolides, azalides, and streptogramins. In: Zinner SH, Young LS, Acar JF, Neu HC, eds. Expanding indications for the new macrolides, azalides, and streptogramins. New York: Marcel Dekker, 1997:27-38.
10. Craig WA, Gudmundsson S. Postantibiotic effect. In: Lorian V, ed. Antibiotics in laboratory medicine. 4th ed. Baltimore: Williams and Wilkins, 1996:296-329.
11. Bigger JW. The bactericidal action of penicillin on Staphylococcus pyogenes: part I. Irish J Med Sci 1944;227:533-68.
12. Eagle H, Musselman AD. The slow recovery of bacteria from the toxic effects of penicillin. J Bacteriol 1949;58:475-90.
13. Parker RF, Luse S. The action of penicillin on staphylococcus: further observations on the effect of a short exposure. J Bacteriol 1948;56: 75-81.
14. Bustamante CI, Drusano GL, Tatem BA, Standiford HC. Postantibiotic effect of imipenem on Pseudomonas aeruginosa. Antimicrob Agents Chemother 1984;26:678-82.
15. Gudmundsson S, Vogelman B, Craig WA. 1986. The in-vivo postantibiotic effect of imipenem and other new antimicrobials. J Antimicrob Chemother 1986;18(suppl E):67-73.
16. Craig WA. Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. J Antimicrob Chemother 1993;31(suppl D):149-58.